Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.7 EUR | -1.21% | -1.21% | -14.16% |
Jan. 30 | Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug | MT |
Jan. 30 | Nanobiotix: targets achieved for NANORAY-312 | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.16% | 290M | - | ||
+9.30% | 46.03B | B | ||
+52.73% | 44.55B | A | ||
+7.15% | 40.8B | B- | ||
-8.78% | 28.25B | C | ||
+18.68% | 27.71B | B- | ||
-21.92% | 18.82B | B | ||
+14.62% | 13.91B | C+ | ||
+31.85% | 12.43B | C+ | ||
+4.47% | 10.81B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Nanobiotix - Euronext Paris
- Ratings Nanobiotix